Key result
Application of site-3 toxin anthopleurin A to the DeltaKPQ mutation resulted in a large negative shift in the Na channel availability curve of nearly -14 mV, enhancing closed-state inactivation.
Why the study?
Does anthopleurin A alter closed-state inactivation in the DeltaKPQ mutated human cardiac Na channel?
Does anthopleurin A alter closed-state inactivation in the DeltaKPQ mutated human cardiac Na channel?
The study demonstrates that closed-state inactivation in toxin-modified DeltaKPQ channels is enhanced, suggesting the mutated inactivation lid is positioned closer to its receptor.
Enhances mechanistic models of DeltaKPQ Na channel gating; leaves open any therapeutic translation.
DeltaKPQ, a three amino acid [lysine (K), proline (P), glutamine (Q)] deletion mutation of the human cardiac Na channel (hH1), which is one cause of long QT syndrome (LQT3), has impaired inactivation resulting in a late sodium current. To better understand inactivation in DeltaKPQ, we applied a site-3 toxin anthopleurin A, which has been shown to inhibit inactivation from the open state with little or no effect on inactivation from the closed state(s) in wild-type hH1. In contrast to the effect of site-3 toxins on wild-type hH1, inactivation from closed state(s) in toxin-modified DeltaKPQ demonstrated a large negative shift in the Na channel availability curve of nearly -14 mV. Recovery from inactivation showed that toxin-modified DeltaKPQ channels recovered slightly faster than those in control, whereas development of inactivation at potentials negative to -80 mV showed that inactivation developed much more rapidly in toxin-modified DeltaKPQ channels compared with control. An explanation for our results is that closed-state inactivation in toxin-modified DeltaKPQ is enhanced by the mutated inactivation lid being positioned "closer" to its receptor resulting in an increased rate of association between the inactivation lid and its receptor.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2002) studied Long QT syndrome (LQT3). Site-3 toxin anthopleurin A vs. Control (wild-type hH1 or untreated DeltaKPQ) was evaluated on Na channel availability curve shift. Application of site-3 toxin anthopleurin A to the DeltaKPQ mutation resulted in a large negative shift in the Na channel availability curve of nearly -14 mV, enhancing closed-state inactivation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: